You have reached the HIVandHepatitis.com legacy site. Please visit our new site at hivandhepatitis.com

 Google Custom Search

Elvitegravir (GS 9137)

Once-Daily Elvitegravir Matches Raltegravir in Phase 3 Study
3-25-2011

Gilead Begins First Phase 3 Clinical Trial of Boosted Elvitegravir Quad Pill
4-16-2010

Gilead's Quad Pill Matches Atripla, New Booster Cobicistat (GS 9350) Looks Good with Atazanavir (Reyataz)
2-19-2010


Gilead Releases 24 Week Data on "Quad" Pill containing Elvitegravir and Experimental Boosting Agent GS 9350
1/08/10


Gilead Plans Clinical Trial of 4-in-1 Antiretroviral Combination Pill Containing Experimental Integrase Inhibitor Elvitegravir
- 1/20/09

Gilead Announces Start of Phase III Efficacy Trial of Experimental Integrase Inhibitor Elvitegravir in Treatment-experienced HIV Patients
7/25/08


 

 

 


 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 


FDA-approved HIV
and AIDS Treatments
Protease Inhibitors PIs
non Nucleoside Reverse
  
Transcriptase Inhibitors nNRTIs
Nucleoside / Nucleotide
  
Reverse Transcriptase Inhibitors NRTIs
Fixed-dose Combinations
Entry / Fusion Inhibitors EIs
Integrase Inhibitors

Experimental Treatments

HIV and AIDS
Articles by Topic
Adverse Events
Opportunistic Infections
Metabolic Complications
Lipodystrophy - Fat Redistribution
Treatment Guidelines
Women/Children